Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Orexin Receptor Antagonist [EPC]

Known as: Orexin Receptor Antagonist 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract Background We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with… Expand
Is this relevant?
2017
2017
Objective Various stressors induce stress responses through the hypothalamic–pituitary–adrenal and the sympathetic–adrenal… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Background: Filorexant (MK-6096) is an orexin receptor antagonist; here, we evaluate the efficacy of filorexant in the treatment… Expand
  • figure 2
Is this relevant?
2016
2016
Insomnia is characterized by difficulty in falling asleep, difficulty maintaining sleep, or experiencing nonrestorative sleep… Expand
  • figure 1
Is this relevant?
2015
2015
Primary insomnia is mainly treated with drugs acting on benzodiazepine receptors and a few other classes of drugs used for… Expand
Is this relevant?
2014
2014
Abstract The combination of stable isotope labeling of amino acids in mammals (SILAM) and laser capture microdissection (LCM) for… Expand
Is this relevant?
2014
2014
Almorexant, a tetrahydroisoquinoline orexin receptor antagonist and first representative of a new class of compounds for the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2014
2014
Almorexant, a dual orexin receptor antagonist, was investigated for the treatment of insomnia. The following observations… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2014
Review
2014
Insomnia persistently affects the quality and quantity of sleep. Currently approved treatments for insomnia primarily target… Expand
Is this relevant?